Loading...
•
Dec 31, 2022
Bioventus Q4 2022 Earnings Report
Reported a decrease in net sales and a net loss compared to the prior-year period.
Key Takeaways
Bioventus reported a decrease in net sales of $125.8 million, down 3.5% year-over-year, and a net loss of $44.9 million, compared to a net loss of $1.9 million in the prior-year period. The decline in sales was primarily due to a decrease in the Pain Treatments vertical, while the Surgical Solutions vertical experienced growth. The company is focused on improving execution and regaining investor confidence in 2023.
Net sales decreased by 3.5% year-over-year to $125.8 million.
Net loss was $44.9 million, a significant increase from the $1.9 million loss in the prior-year period.
Adjusted EBITDA decreased to $15.2 million, compared to $28.5 million in the prior-year period.
Loss per share of Class A common stock was $0.52, compared to $0.01 in the prior-year period.
Bioventus
Bioventus
Forward Guidance
No specific forward guidance provided in the document.